Author:
Lozano Ana Belén,Chueca Natalia,de Salazar Adolfo,Fernández-Fuertes Elisa,Collado Antonio,Fernández Juan Manuel,Álvarez Marta,García Federico
Funder
FEDER
Fundación Progreso y Salud, Junta de Andalucia
Reference19 articles.
1. Andrea-Garnier, E., Marcellin, AG., Reliquet, V., et al. Unpublished results. Bictegravir Virology Failure with Emergence of a Previously Unreported Mutation in the Integrase Gene.
2. Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I;Andreatta;J. Antimicrob. Chemother.,2019
3. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial
4. DIVEIN: a web server to analyze phylogenies, sequence divergence, diversity, and informative sites;Deng;Biotechnology,2010
5. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial;Gallant;Lancet,2017
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献